Historical bdx News Stories
BDX Profit Outlook Cut Triggers Big Share Drop -Q1
Becton Dickinson lowered its full-year adjusted EPS outlook sharply after reporting Q1 results that beat revenue but missed profit expectations. The guidance reset, capacity investments for prefillable syringes, and selective product clearances are driving near-term volatility while preserving longer-term growth levers.
BDX: CE Mark for Revello Stent, Debt Upsize Boosts
Becton Dickinson secured CE Mark for its Revello vascular stent and expanded a major debt tender offer, moves that shift commercial and capital priorities. Market response was muted, but these developments strengthen BD's path as a focused medical-technology company.
BDX Pivot: Alaris Growth and Syringe Expansion Now
This week Becton Dickinson (BDX) completed its strategic spin-off and reinforced core growth drivers: Alaris infusion adoption, a Nebraska Neopak syringe line, and a 5.5 mL Neopak XtraFlow development. Financials reflect the new pure-play profile with updated EPS guidance and renewed emphasis on delivery systems tied to biologic therapies.
BDX Boosts Domestic Syringe Capacity, Partnerships
Becton Dickinson (BDX) continues executing its “New BD” strategy with a $110M U.S. syringe capacity expansion, a large‑volume syringe collaboration with Ypsomed, and commercial integrations that improve hospital interoperability. No material BDX news emerged in the past week, but February strategic moves remain primary drivers for the stock.
BDX: FDA Clearance, $4B Cash & New Devices
Becton Dickinson (BDX) advanced its MedTech focus this week with FDA 510(k) clearance for a new Surgiphor irrigation system, the launch of a Vacutainer urine collection kit, and completion of its Biosciences & Diagnostic Solutions spin‑off combined with Waters. The transaction generated $4 billion in cash for BD — split between accelerated buybacks and debt reduction — while the stock has seen notable near‑term pressure. These concrete developments sharpen BD’s strategic profile and create near‑term capital deployment dynamics for investors to monitor.
BDX Spins Off, $4B Cash, $2B Buybacks Announced Up
Becton, Dickinson completed its Waters merger spin‑off, received $4B in cash, and outlined $2B in accelerated buybacks plus $2B to repay debt. Q1 FY2026 results beat consensus but Life Sciences lagged, driving short-term stock volatility amid mixed analyst reactions.
BDX Tightens Focus After Waters Spin-Off
Becton, Dickinson (BDX) completed the Waters spin-off, received $4 billion in cash, and launched debt buybacks while reporting strong Q4 results alongside reduced FY26 EPS guidance—moves that reshape its capital structure and strategic profile as a pure-play medical technology company.
BDX Waters Deal Closes: $4B Cash, Buybacks & Spin.
Becton, Dickinson & Co. (BDX) completed the Waters reverse Morris Trust spin today, unlocking about $4 billion in proceeds. Management earmarks at least half for share repurchases and the remainder for debt reduction, while new product clearances and AI-driven lab tools support the company’s growth path as it refocuses after the Biosciences/Diagnostics separation.